ImmunoPrecise Antibodies (IPA) is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. We aim to transform the conventional, multi-vendor, product development model by bringing advanced high-throughput, data-driven technologies to our partners. We incorporate the advantages of diverse antibody repertoires with our therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes.
ImmunoPrecise brings resourceful solutions, adaptable approaches, and insightful collaboration to every program. Our single-source model, fast turn-around times and >95% success rate can greatly accelerate the critically important research of our global partners.